Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Abstract Introduction Allergic comorbidities are common in patients with atopic dermatitis (AD). Individual trials with abrocitinib or dupilumab demonstrated efficacy and safety in patients with moderate-to-severe AD and allergic comorbidities. This post hoc analysis of the phase 3 JADE COMPARE and...

Descripció completa

Dades bibliogràfiques

Autors principals:	Eric L. Simpson, Jonathan I. Silverberg, Bob Geng, José-Manuel Carrascosa, Thomas Bieber, Patrick M. Brunner, Delphine Staumont-Sallé, Chao Ji, Pinaki Biswas, Claire Feeney, Irene Hernández-Martín, Francisco José Rebollo Laserna, Herwig Koppensteiner
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2025-09-01
Col·lecció:	Dermatology and Therapy
Matèries:	Abrocitinib Allergic rhinitis Asthma Comorbidity Dupilumab Food allergy
Accés en línia:	https://doi.org/10.1007/s13555-025-01516-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!